Infinity Pharmaceuticals Inc (INFI)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Infinity Pharmaceuticals Inc (INFI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012291
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Infinity Pharmaceuticals Inc (Infinity Pharmaceuticals) is a biopharmaceutical company, which discovers and develops medicines to people suffering with difficult-to-treat diseases. It focuses on small molecule drugs designed to address diseases in the areas of cancer and inflammation. The company’s product pipeline comprises lead product candidate, duvelisib, also known as IPI-145 is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) in Phase 3. The product is being evaluated in various product development stages for the treatment of indolent non-Hodgkin lymphoma (iNHL), chronic lymphocytic leukemia (CLL) and advanced hematologic malignancies. Infinity Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.

Infinity Pharmaceuticals Inc (INFI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 10
Partnerships 11
Bristol-Myers Squibb Expands Agreement with Infinity Pharma 11
Pharm-Olam International Enters into Agreement with Infinity Pharma 12
Lead Discovery Center Partners with Infinity Pharma 13
Infinity Pharma Extends Co-Development Agreement With Mundipharma 14
Licensing Agreements 16
PellePharm Enters into Licensing Agreement with Infinity Pharma 16
Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 17
FAAH Pharma Enters into Licensing Agreement with Infinity Pharma 19
Infinity Pharma Amends Licensing Agreement with Millennium Pharma 20
Equity Offering 22
Infinity Pharmaceuticals to Raise USD50 Million in Offering of Common Stock 22
Infinity Pharma Completes Public Offering Of Common Stock For US$173 Million 23
Infinity Pharma Completes Private Placement Of Shares For US$78.5 Million 25
Infinity Pharma Completes Public Offering Of Common Stock For US$88 Million 26
Infinity Pharmaceuticals Inc – Key Competitors 28
Infinity Pharmaceuticals Inc – Key Employees 29
Infinity Pharmaceuticals Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Strategy And Business Planning 31
Jan 11, 2016: Infinity Provides Key 2016 Goals and Financial Guidance 31
Financial Announcements 32
Nov 07, 2017: Infinity Provides Company Update and Reports Third Quarter 2017 Financial Results 32
Aug 03, 2017: Infinity Provides Company Update and Reports Second Quarter 2017 Financial Results 34
May 09, 2017: Infinity Provides Company Reports First Quarter 2017 Financial Results 37
Mar 14, 2017: Infinity Provides Company Update and Reports Fourth Quarter 2016 Financial Results 38
Nov 09, 2016: Infinity Provides Company Update and Reports Third Quarter 2016 Financial Results 40
Aug 09, 2016: Infinity Provides Company Update And Reports Second Quarter 2016 Financial Results 42
May 04, 2016: Infinity Provides Company Update And Reports First Quarter 2016 Financial Results 44
Feb 23, 2016: Infinity Provides Company Update and Reports Full-Year 2015 Financial Results 46
Corporate Communications 48
Feb 13, 2017: Infinity Announces Promotion of Jeffery Kutok, M.D., Ph.D. to Chief Scientific Officer 48
Jan 04, 2017: Infinity Announces Organizational Changes 49
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Infinity Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 10
Bristol-Myers Squibb Expands Agreement with Infinity Pharma 11
Pharm-Olam International Enters into Agreement with Infinity Pharma 12
Lead Discovery Center Partners with Infinity Pharma 13
Infinity Pharma Extends Co-Development Agreement With Mundipharma 14
PellePharm Enters into Licensing Agreement with Infinity Pharma 16
Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 17
FAAH Pharma Enters into Licensing Agreement with Infinity Pharma 19
Infinity Pharma Amends Licensing Agreement with Millennium Pharma 20
Infinity Pharmaceuticals to Raise USD50 Million in Offering of Common Stock 22
Infinity Pharma Completes Public Offering Of Common Stock For US$173 Million 23
Infinity Pharma Completes Private Placement Of Shares For US$78.5 Million 25
Infinity Pharma Completes Public Offering Of Common Stock For US$88 Million 26
Infinity Pharmaceuticals Inc, Key Competitors 28
Infinity Pharmaceuticals Inc, Key Employees 29
Infinity Pharmaceuticals Inc, Subsidiaries 30

★海外企業調査レポート[Infinity Pharmaceuticals Inc (INFI)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • PT PLN (Persero):企業の戦略的SWOT分析
    PT PLN (Persero) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Sino Land Co Ltd:企業の戦略・SWOT・財務情報
    Sino Land Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Sino Land Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • COWI AS:企業の戦略的SWOT分析
    COWI AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • NextEra Energy Inc (NEE):企業の財務・戦略的SWOT分析
    NextEra Energy Inc (NEE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • CenterPoint Energy Inc (CNP)-石油・ガス分野:企業M&A・提携分析
    Summary CenterPoint Energy, Inc. (CenterPoint) is an energy utility company. The company through its subsidiaries offers electricity transmission and distribution, natural gas distribution, natural gas sales and services, pipelines services and other field services. It sells regulated intrastate nat …
  • Armanino Foods of Distinction Inc.:企業の戦略・SWOT・財務情報
    Armanino Foods of Distinction Inc. - Strategy, SWOT and Corporate Finance Report Summary Armanino Foods of Distinction Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • BBB Technologies Inc:企業の製品パイプライン分析2018
    Summary BBB Technologies Inc (BBB Tech) is a development stage medical technology company that develops medical devices and applications that facilitate the early diagnosis of metabolic and cardiovascular disorders. The company discovers and develops single-drop and mobile integrated diagnostic tool …
  • American Axle & Manufacturing Holdings, Inc.
    American Axle & Manufacturing Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary American Axle & Manufacturing Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • Alabama Power Co:電力:M&Aディール及び事業提携情報
    Summary Alabama Power Co (Alabama Power), a subsidiary of Southern Company, is a vertically-integrated utility that undertakes the generation, transmission, distribution, procurement and sale of electricity. It generates electricity from coal, hydro, natural gas, oil and nuclear sources. Alabama Pow …
  • Kepler Weber SA (KEPL3):企業の財務・戦略的SWOT分析
    Kepler Weber SA (KEPL3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • IGas Energy PLC (IGAS):企業の財務・戦略的SWOT分析
    IGas Energy PLC (IGAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Norfolk Southern Corporation:企業の戦略・SWOT・財務分析
    Norfolk Southern Corporation - Strategy, SWOT and Corporate Finance Report Summary Norfolk Southern Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • BEENOS Inc.:企業のM&A・事業提携・投資動向
    BEENOS Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BEENOS Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • ORBCOMM Inc (ORBC):企業の財務・戦略的SWOT分析
    ORBCOMM Inc (ORBC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • The British United Provident Association Ltd-製薬・医療分野:企業M&A・提携分析
    Summary The British United Provident Association Ltd (Bupa) is a leading global healthcare group. It offers health insurance and other funding products, chronic disease management services, home healthcare services, workplace health services and care services, comprising residential and nursing home …
  • A&D Company Ltd (7745):企業の財務・戦略的SWOT分析
    Summary A&D Company Ltd (A&D Company) is a medical equipment company that manufactures, designs, develops, and distributes advanced measuring, controlling, monitoring, and testing instruments. The company’s products include powertrain testing systems, digital analog converter, DSP platform, model ba …
  • Fujifilm SonoSite Inc:医療機器:M&Aディール及び事業提携情報
    Summary Fujifilm SonoSite Inc (Fujifilm SonoSite), a subsidiary of Fujifilm Holdings Corp, is a medical device company. It designs and develops ultrasound systems for use in a variety of medical specialties including anesthesiology, cardiology, critical care, endocrinology, orthopedic surgery, radio …
  • PT Bank Permata Tbk:企業の戦略・SWOT・財務分析
    PT Bank Permata Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Bank Permata Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Epic Systems Corp:企業の戦略的SWOT分析
    Epic Systems Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Symphogen AS:企業の戦略的SWOT分析
    Symphogen AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆